Clinical trials: Squamous Non-Small Cell Lung Cancer
Prostate Cancer, Melanoma
Safety Study of MGA271 in Refractory Cancer
The purpose of this study is to evaluate the safety of MGA271 when given by intravenous (IV) infusion to patients with refractory cancer.
- Conditions
- Prostate Cancer, Melanoma, Renal Cell Carcinoma, Triple-negative Breast Cancer
- Trial name
- NCT01391143
- Testing
- MGA271
- Where
- 12 sites in United States
- Volunteers
- 179 people
- Sponsor
- MacroGenics
Carcinoma, Non-Squamous Non-Small-Cell Lung Cancer
A Study of Paclitaxel/Carboplatin With or Without CDP791 in Patients With Lung Cancer
A 2-part study to examine safety, tolerability and pharmacokinetics (part 1), and anti-tumour effects (part 2), of CDP791 combined with carboplatin and paclitaxel.
- Trial name
- NCT00152477
- Testing
- Carboplatin, Paclitaxel, CDP791 10mg/kg
- Where
- 21 sites in Hungary, Poland and 1 more
- Volunteers
- 165 people
- Sponsor
- UCB Pharma
Advanced Solid Tumors, Non-Small Cell Lung Cancer
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous ABBV-253 Moves Through the Body in Adult Participants With Advanced Solid Tumors
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events, change in disease activity and pharmacokinetics of ABBV-253.
- Conditions
- Advanced Solid Tumors, Non-Small Cell Lung Cancer, Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT07807956
- Testing
- ABBV-253
- Where
- 3 sites in United States
- Volunteers
- 130 people
- Sponsor
- AbbVie
Metastatic Non-Squamous Non-Small Cell Lung Cancer
Phase 3 Study of Sitravatinib Plus Nivolumab vs Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer
This study will compare the efficacy of the investigational agent sitravatinib in combination with nivolumab versus docetaxel in patients with advanced non-squamous NSCLC who have previously experienced disease progression on or…
- Trial name
- SAPPHIRE (NCT03906071)
- Testing
- Nivolumab, Sitravatinib, Docetaxel
- Where
- 261 sites in United States, Belgium and 10 more
- Volunteers
- 577 people
- Sponsor
- Mirati Therapeutics Inc.
NSCLC
A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation
This is a randomized, positive controlled, open-Label and multicenter phase III study, to evaluate the efficacy and safety of Sosimerasib in combination with IN10018 versus anti-PD-1 monoclonal antibody in combination with…
- Trial name
- NCT07833202
- Testing
- Sosimerasib in combination with IN10018, Tislelizumab + Carboplatin + Pemetrexed
- Where
- China
- Volunteers
- 416 people
- Sponsor
- Shanghai Jeyou Pharmaceutical Co., Ltd.
Renal Cell Carcinoma, Melanoma
Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab
In this study, the Phase Ib portion aims to establish safety and tolerability of ARRY-614 with either nivolumab or ipilimumab and to determine a recommended phase II dose of ARRY-614 in combination with either nivolumab or…
- Conditions
- Renal Cell Carcinoma, Melanoma, Solid Tumor, Non-small Cell Lung Cancer
- Trial name
- NCT04074967
- Testing
- Phase Ib ARRY-614 + nivolumab, Phase Ib ARRY-614 + nivolumab+ipilimumab, Phase II ARRY-614 + nivolumab
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Dan Zandberg
Non-small Cell Lung Cancer
Tiragolumab and Atezolizumab in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC) and Untreated Brain Metastases
This clinical trial is aimed at the evaluation of the safety and clinical activity of tiragolumab in combination with atezolizumab with or without chemotherapy in the first line treatment of metastatic non-squamous NSCLC patients…
- Trial name
- NCT05746481
- Testing
- Tiragolumab, Atezolizumab, Pemetrexed
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Liza Villaruz, MD
Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma
Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)
This phase II LUNG-MAP treatment trial studies how well combination treatment (talazoparib plus avelumab) works in treating patients with non-squamous non-small cell lung cancer that has an STK11 gene mutation and has come back…
- Conditions
- Advanced Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT04173507
- Testing
- Avelumab, Talazoparib, Talazoparib Tosylate
- Where
- 325 sites in United States
- Volunteers
- 47 people
- Sponsor
- SWOG Cancer Research Network
Solid Tumor, Adult, Solid Tumor
A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
The goal of this study is to test A2B530,an autologous logic-gated Tmod™ CAR T-cell product in subjects with solid tumors including colorectal cancer (CRC), pancreatic cancer (PANC), non-small cell lung cancer (NSCLC), and other…
- Conditions
- Solid Tumor, Adult, Solid Tumor, Pancreatic Cancer, Pancreatic Neoplasms
- Trial name
- EVEREST-1 (NCT05736731)
- Testing
- A2B530, xT-Onco with HLA-LOH Assay
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- A2 Biotherapeutics Inc.
Advanced Solid Tumors
A Study to Learn How Safe the Study Drug BAY 2416964 (AhR Inhibitor) in Combination With the Treatment Pembrolizumab is, How This Combination Affects the Body, the Maximum Amount That Can be Given, How it Moves Into, Through and Out of the Body and Its Action Against Advanced Solid Cancers in Adults
Researchers are looking for a better way to treat advanced solid cancers including head and neck cancer, lung cancer and bladder cancer.
- Trial name
- NCT04999202
- Testing
- BAY2416964, Pembrolizumab
- Where
- 14 sites in United States, Italy and 2 more
- Volunteers
- 47 people
- Sponsor
- Bayer
Non-small Cell Lung Cancer
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants…
- Trial name
- DESTINY-Lung06 (NCT06899126)
- Testing
- Trastuzumab Deruxtecan, pembrolizumab, Pemetrexed
- Where
- 246 sites in United States, Argentina and 22 more
- Volunteers
- 686 people
- Sponsor
- Daiichi Sankyo
Non-small Cell Lung Cancer
Efficacy of Cadonilimab in Non-squamous Non-small Cell Lung Cancer Patients Resistant to EGFR-TKI
This study was designed to evaluate the efficacy and safety of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) in combination with pemetrexed and anlotinib for treatment of elderly patients with T790M-negative advanced…
- Trial name
- NCT06277674
- Testing
- Cadonilimab plus Pemetrexed and Anlotinib
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Guangzhou University of Traditional Chinese Medicine
Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer
Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
This phase II trial is studying how well docetaxel given together with cisplatin and pegfilgrastim followed by erlotinib hydrochloride works in treating patients with stage IIIB or stage IV non-small cell lung cancer.
- Conditions
- Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Bronchoalveolar Cell Lung Cancer, Large Cell Lung Cancer
- Trial name
- NCT01557959
- Testing
- cisplatin, pegfilgrastim, erlotinib hydrochloride
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Wake Forest University Health Sciences
Carcinoma, Non-Small-Cell Lung
TAilored Post-Surgical Therapy in Early Stage NSCLC
Our hypothesis is that patients receiving therapy based on their baseline tumor ERCC1 levels and EGFR mutations would attain better disease free survival rates than patients in the control arm receiving noncustomized therapy.
- Trial name
- TASTE (NCT00775385)
- Testing
- Standard Chemotherapy, Customized Treatment
- Where
- 42 sites in France
- Volunteers
- 152 people
- Sponsor
- Intergroupe Francophone de Cancerologie Thoracique
Lung Cancer Stage II
Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment
A single-arm, prospective, single-center, phase II, exploratory study investigating Camrelizumab combined with pemetrexed and carboplatin in the treatment of advanced non-squamous cell non-small-scale EGFR mutations (EGFR-TKI…
- Trial name
- NCT04970043
- Testing
- Camrelizumab+ pemetrexed + platinum
- Volunteers
- 58 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Non-small Cell Lung Cancer Metastatic
Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)
Primary Objectives: Doublet Cohort Part 1 (safety run-in): To assess the tolerability and to confirm the recommended dose of tusamitamab ravtansine in combination with ramucirumab in the NSQ NSCLC population.
- Trial name
- CARMEN-LC04 (NCT04394624)
- Testing
- SAR408701, ramucirumab, pembrolizumab
- Where
- 13 sites in United States, Bulgaria and 4 more
- Volunteers
- 31 people
- Sponsor
- Sanofi
Lung Cancer
Carboplatin, Paclitaxel, Selenomethionine, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery
RATIONALE: Drugs used in chemotherapy, such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00526890
- Testing
- selenomethionine, carboplatin, paclitaxel
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Roswell Park Cancer Institute
Lung Cancer
Combination Chemotherapy and Computer-Planned Radiation Therapy in Treating Patients With Unresectable Stage III Non-Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00033553
- Testing
- carboplatin, gemcitabine hydrochloride, paclitaxel
- Where
- 74 sites in United States
- Volunteers
- 69 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lung Cancer
PD1 and PARP for Maintenance Therapy in NSLLC
PARP inhibitor and PD1 in lung squamous cell carcinoma The current study will compare PD1 plus maintenance PARP for the treatment of squamous NSCLC.
- Trial name
- NCT05392686
- Testing
- PD-1 inhibitor, PARP inhibitor
- Where
- China
- Volunteers
- 52 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.